Hemab Therapeutics (NASDAQ:COAG) Upgraded to Strong-Buy at Rodman & Renshaw

Rodman & Renshaw upgraded shares of Hemab Therapeutics (NASDAQ:COAG) to a strong-buy rating in a research report report published on Monday morning,Zacks reports.

Several other research analysts have also weighed in on COAG. Jefferies Financial Group increased their price objective on shares of Hemab Therapeutics from $39.00 to $47.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Weiss Ratings downgraded shares of Hemab Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, September 25th. Wedbush boosted their target price on shares of Hemab Therapeutics from $55.00 to $64.00 and gave the company an “outperform” rating in a report on Wednesday, August 12th. Finally, HC Wainwright upped their price target on shares of Hemab Therapeutics from $52.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Hemab Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $52.17.

Hemab Therapeutics Price Performance

NASDAQ COAG opened at $29.80 on Monday. The stock’s 50-day simple moving average is $42.06. Hemab Therapeutics has a twelve month low of $23.00 and a twelve month high of $55.42. The stock has a market capitalization of $1.39 billion and a P/E ratio of -1.20.

Hemab Therapeutics (NASDAQ:COAG) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.17). Sell-side analysts predict that Hemab Therapeutics will post -3.09 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State Street Corp acquired a new stake in Hemab Therapeutics during the second quarter worth about $2,825,000. Opaleye Management Inc. acquired a new position in shares of Hemab Therapeutics in the 2nd quarter valued at about $1,750,000. The Manufacturers Life Insurance Company acquired a new position in shares of Hemab Therapeutics in the 2nd quarter valued at about $688,000. Squarepoint Ops LLC acquired a new position in shares of Hemab Therapeutics in the 2nd quarter valued at about $230,000. Finally, Citadel Advisors LLC purchased a new stake in shares of Hemab Therapeutics during the 2nd quarter worth about $19,226,000.

Hemab Therapeutics Company Profile

Hemab Therapeutics (NASDAQ: COAG) is a clinical-stage biopharmaceutical company developing treatments for serious and potentially life-threatening bleeding disorders. The company focuses on rare conditions for which existing therapies may be limited, inconvenient, or ineffective for some patients.

Hemab’s lead investigational program, HMB-001, is an engineered bispecific antibody designed to improve blood clotting by enhancing thrombin generation through inhibition of tissue factor pathway inhibitor.